Fig. 2: AdC68–CR9114 prophylactically and therapeutically protected mice from pH1N1 infection.

For the prophylactic experiments, mice were divided into different groups and immunized with AdC68–CR9114 or AdC68–empty (5 × 10¹⁰ vp/mouse) via tail intravenous or intranasal immunization. Mice were challenged intranasally with 10LD50 of the pH1N1 influenza virus. Body weight and survival rate were monitored for 2 weeks. For the therapeutic experiments, mice were infected with 10LD50 of the pH1N1 virus, and intravenously or intranasally treated with 5 × 10¹⁰ vp AdC68–CR9114 or AdC68–empty virus at 6 h following the influenza challenge. a, b Weight loss and survival rate in the prophylactic group treated intravenously and challenged with pH1N1. c, d Weight loss and survival rate in the prophylactic group treated intranasally and challenged with pH1N1. e, f Weight loss and survival rate in the therapeutic groups treated intravenously with AdC68–CR9114 and challenged with pH1N1. g, h Weight loss and survival rate in the therapeutic group treated intranasally with AdC68–CR9114 and challenged with pH1N1. Five mice in each group. Data in a, c, e, g are expressed as mean ± SD.